These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17047119)

  • 1. Safe and effective application of anti-TNF-alpha in a patient infected with HIV and concomitant Crohn's disease.
    Beltrán B; Nos P; Bastida G; Iborra M; Hoyos M; Ponce J
    Gut; 2006 Nov; 55(11):1670-1. PubMed ID: 17047119
    [No Abstract]   [Full Text] [Related]  

  • 2. [Adalimumab in infliximab refractory Crohn's disease -- the next generation of anti-TNF-alpha-therapy?].
    Heidemann J; Kucharzik T
    Z Gastroenterol; 2005 Jul; 43(7):689-90. PubMed ID: 16001352
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cytomegalovirus primary infection in a patient with Crohn's disease treated with azathioprine and anti-TNF alpha].
    Ben Hriz F; Habbessi H; Maamouri N; Belkahla N; Ouerdiane S; Chouaib S; Ouerghi H; Chaabouni H; Ben Mami N
    Tunis Med; 2009 Aug; 87(8):545-6. PubMed ID: 20180364
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF.
    Holtmann MH; Galle PR; Neurath MF
    Am J Gastroenterol; 2003 Feb; 98(2):504-5. PubMed ID: 12591081
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
    de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
    Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: infliximab for Crohn's disease treatment--shifting therapeutic strategies after 10 years of clinical experience.
    Danese S; Colombel JF; Reinisch W; Rutgeerts PJ
    Aliment Pharmacol Ther; 2011 Apr; 33(8):857-69. PubMed ID: 21320139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumour necrosis factor-alpha therapies in Crohn's disease.
    Sprakes MB; Hamlin PJ
    Br J Hosp Med (Lond); 2009 Nov; 70(11):644-7. PubMed ID: 20081592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
    Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
    Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fifteen years of use of anti-TNF antibodies in moderate to severe Crohn's disease: how to make the best of this experience].
    Louis E; Reenaers C; Meuwis MA; Van Kemseke C; Latour P; Chapelier N; Wertz S; Coïmbra C; Meunier P; Belaiche J
    Rev Med Liege; 2012; 67 Spec No():8-13. PubMed ID: 22690480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Closing fistulas in Crohn's disease--should the accent be on maintenance or safety?
    Fiocchi C
    N Engl J Med; 2004 Feb; 350(9):934-6. PubMed ID: 14985492
    [No Abstract]   [Full Text] [Related]  

  • 11. Mechanism and therapeutic strategy of secondary failure to anti-tumor necrosis factor-α monoclonal antibody treatment for Crohn's disease.
    Matsuoka K; Kanai T
    Digestion; 2013; 88(1):17-9. PubMed ID: 23797247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgery for adult Crohn's disease: what is the actual risk?
    Bouguen G; Peyrin-Biroulet L
    Gut; 2011 Sep; 60(9):1178-81. PubMed ID: 21610273
    [No Abstract]   [Full Text] [Related]  

  • 14. Practical application of anti-TNF therapy for luminal Crohn's disease.
    Kamm MA; Ng SC; De Cruz P; Allen P; Hanauer SB
    Inflamm Bowel Dis; 2011 Nov; 17(11):2366-91. PubMed ID: 21337669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of Crohn's disease with anti TNF alpha antibodies--the experience in the Tel Aviv Medical Center].
    Dotan I; Yeshurun D; Hallak A; Horowitz N; Tiomny E; Reif S; Halpern Z; Rachmilewitz D
    Harefuah; 2001 Apr; 140(4):289-93, 368. PubMed ID: 11303390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Selective TNF-alpha inhibition in Crohn disease. Emergency help in problem cases].
    MMW Fortschr Med; 2001 May; 143(18):52. PubMed ID: 11387713
    [No Abstract]   [Full Text] [Related]  

  • 17. [What can be expected from biological therapies for Crohn's disease?].
    Lemann M
    Gastroenterol Clin Biol; 2001 Nov; 25(11):945-7. PubMed ID: 11845043
    [No Abstract]   [Full Text] [Related]  

  • 18. Disseminated tuberculosis in a Crohn's disease patient on anti-TNF alpha therapy despite chemoprophylaxis.
    Bourikas LA; Kourbeti IS; Koutsopoulos AV; Koutroubakis IE
    Gut; 2008 Mar; 57(3):425; author reply 425-6. PubMed ID: 18268059
    [No Abstract]   [Full Text] [Related]  

  • 19. How to manage difficult Crohn's disease: optimum delivery of anti-TNFs.
    Krygier DS; Ko HH; Bressler B
    Expert Rev Gastroenterol Hepatol; 2009 Aug; 3(4):407-15. PubMed ID: 19673627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab (Remicade), a new biological treatment for Crohn's disease.
    D'Haens GR
    Ital J Gastroenterol Hepatol; 1999; 31(6):519-20. PubMed ID: 10575573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.